FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 2024, at 8:00 a.m., EDT, to provide a comprehensive overview of recent data from its pivotal trial of iopofosine I 131 in Waldenstrom's macroglobulinemia, the current treatment landscape, unmet needs for patients with t ...

FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 2024, at 8:00 a.m., EDT, to provide a comprehensive overview of recent data from its pivotal trial of iopofosine I 131 in Waldenstrom’s macroglobulinemia, the current treatment landscape, unmet needs for patients with ...

Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin's Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. FLORHAM PARK, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, announced today a strategic partnership with City of Hope Canc ...

Thomas Barwick/DigitalVision via Getty Images Topline Summary and Update Cellectar Biosciences, Inc. (NASDAQ:CLRB) is a radiopharmaceutical-focused developmental biotech training their sites on a first approval in Waldenstrom's macroglobulinemia, a type of slow-growing non-Hodgkin lymphoma that does not have many options for patients who progress in their disease. When I first covered them back in February, I warned readers that this company had the air of something big brewing while the market appears ...

First Quarter – March 31 2024 Financial Update Call May 14, 2024 NASDAQ: CLRB Forward Looking Statements and Disclaimers ...

财务数据和关键指标变化 - 公司2024年3月31日的现金及现金等价物余额为4000万美元,较2023年12月31日的960万美元大幅增加 [18] - 本季度经营活动净现金流出约1340万美元 [18] - 本季度研发费用约740万美元,较2023年同期的670万美元有所增加 [19][20] - 本季度一般及行政费用为460万美元,较2023年同期的210万美元大幅增加,主要是为准备2025年产品上市而增加的基础设施和信息支持成本 [21] - 本季度有990万美元的非现金费用,主要是由于对认股权证的会计处理产生的估值变动 [22][23][24] 各条业务线数据和关键指标变化 - 公司未提供具体的业务线数据和关键指标变化 各个市场数据和关键指标变化 - 公司未提供具体的各个市场数据和关键指标变化 公司战略和发展方向及行业竞争 - 公司正在准备提交沃登斯特罗姆巨球蛋白血症(WM)新药申请,预计2025年获批上市 [7][8] - 公司正在开发三种独特的内部开发的α粒子发射剂,包括CLR 121225,计划于2025年第一季度启动一项实体瘤的I期临床试验 [14][55] - 公司正在开展一项I期临床试验,评估iopofosine I 131在复发/难治性儿童高级别胶质瘤中的疗效,预计2024年下半年提供更新 [15] - 公司已与美国肿瘤网络(AON)建立战略合作伙伴关系,共同推进WM治疗 [13] - 公司正在建立灵活的模块化制造策略,提高供应链的灵活性和可扩展性 [46][47][48][49][50][51][52] 管理层对经营环境和未来前景的评论 - 公司对iopofosine I 131在WM和其他实体瘤/血液肿瘤中的潜力表示乐观 [10][55] - 公司认为WM市场集中度高,未满足的医疗需求大,iopofosine有机会在该市场获得领导地位 [31][32][33][34][35][36][40] - 公司认为iopofosine的产品特征,如无需剂量测定、输注时间短、储存期长、使用方便等,是其相比现有放射性疗法的重要优势 [28] 问答环节重要的提问和回答 问题1 **Ahu Demir 提问** - 公司NDA申报的时间线是什么?是否已经开始招聘销售团队?对于定价有何考虑? [59][60][61][62][63][64][65] **公司回答** - 公司计划在今年下半年提交NDA申请,预计获得6个月的优先审评期 [60] - 公司正在评估建立自有销售团队或使用合同销售团队的方式,正在根据市场数据进行有针对性的招聘 [62][63][64][65] - 公司认为可以对iopofosine进行溢价定价,正在进行定价研究,参考了CAR-T疗法、Azedra以及BTKi在WM治疗中的定价水平 [71][72][73][74] 问题2 **Jeff Jones 提问** - 公司能否分享一下即将在6月公布的WM试验数据的具体情况,如患者数量、之前3例近完全缓解是否有进一步转化? [70][71][72][73][74] **公司回答** - 公司将公布包括总体反应率、主要反应以及反应持续时间在内的关键数据,患者数量将从之前公布的41例增加到50例左右 [72][73][74] - 之前3例近完全缓解的患者的进一步转化情况,公司将在6月的数据公布中予以更新 [72] 问题3 **Jonathan Aschoff 提问** - 公司是否在与潜在的海外合作伙伴进行谈判,他们是否要求设置一些回购条款? [81][82][83][84][85][86][87][88][89][90] **公司回答** - 公司正在与多个区域性和全球性的潜在合作伙伴进行深入探讨,并正在评估不同的合作模式 [82][83][84] - 公司在与合作伙伴的谈判中,会考虑设置一些回购条款,以便未来能够灵活调整合作方式 [85][86] - 公司在定价方面参考了CAR-T疗法、Azedra以及BTKi在WM治疗中的定价水平 [88][89]

Exhibit 99.1 Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 – Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2024, and pr ...

Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2024, and provided a corporate update. "We plan to announce data from our CLOVER WaM pivotal study e ...

Table of Contents U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q [mark one] ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______________ to ______________ Commission File Number 1-36598 CELLECTAR BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) DELA ...

FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that Jarrod Longcor, chief operating officer of Cellectar, will present an overview of the company in a fireside chat at the upcoming Guggenheim Healthcare Talks Radiopharmaceuticals Day being held on May 13, 2024 in New York City. Details of the firesi ...